Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Khisi Mdluli"'
Autor:
Vijender Panduga, Manoranjan Panda, Radha Shandil, Shridhar Narayanan, Naveen Kumar, M Sreenivasaiah, Monalisa Chatterji, Pravin S. Shirude, Claire Sadler, Vasan K. Sambandamurthy, Tommasi Ruben A, Supreeth Guptha, Jyothi Mahadevaswamy, Meenakshi Mallya, Pravin Iyer, Sreevalli Sharma, Vasanthi Ramachandran, Christopher B. Cooper, Anisha Ambady, Ashwini Narayan, Manjunatha M R, Khisi Mdluli, Scott Butler
Publikováno v:
ACS Med Chem Lett
[Image: see text] We report a novel benzimidazole (BI) based DprE1 inhibitor that resulted from scaffold morphing of a 1,4-azaindole series. The clinical progression of the 1,4-azaindole series from our previous work validates the potential of explor
Autor:
Peter S. Kim, Catharina Boehme, William A. Wells, Barry N. Kreiswirth, Michael E. Kimerling, Trevor Peter, Khisi Mdluli, Colleen Daniels, Frank Cobelens, Marco Schito, David W. Dowdy, Mark D. Perkins, Madhukar Pai, Jan Gheuens, Christian Lienhardt, Elizabeth Gardiner, Matteo Zignol, Alimuddin Zumla
Publikováno v:
Lancet infectious diseases, 13(5), 449-458. Lancet Publishing Group
Summary New tuberculosis drug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance. To minimise turnaround time, rapid DST will need to be prioritised, but developers of these assays will need better data about
Evaluation of Moxifloxacin-Containing Regimens in Pathologically Distinct Murine Tuberculosis Models
Autor:
Eric L. Nuermberger, Si Yang Li, Khisi Mdluli, Anne J. Lenaerts, Scott M. Irwin, Paul J. Converse
In the recently concluded REMox-TB trial, two 4-month moxifloxacin-containing regimens did not meet the criteria for noninferiority compared to the current 6-month first-line regimen to treat tuberculosis (TB). Despite the disappointing result, this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8708c1776ec91d6cee0c40eac7c223c6
https://europepmc.org/articles/PMC4468727/
https://europepmc.org/articles/PMC4468727/
Autor:
M. R. Manjunatha, K.R. Prabhakar, Claire Sadler, Pravin S. Shirude, Shridhar Narayanan, Vasanthi Ramachandran, Jitendar Reddy, Suresh Solapure, Monalisa Chatterji, Naveen Kumar, Christopher B. Cooper, Ramanatha Saralaya, Radha Shandil, Sreevalli Sharma, Pravin Iyer, Vijender Panduga, Khisi Mdluli
Publikováno v:
Antimicrobial agents and chemotherapy. 58(9)
New therapeutic strategies against multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis are urgently required to combat the global tuberculosis (TB) threat. Toward this end, we previously reported the identificati
Autor:
Vijender Panduga, Robert Nanduri, Pravin Iyer, Manoranjan Panda, Lalit kumar Jena, Claire Sadler, Anisha Ambady, Sudha Ravishankar, Rudrapatna S. Suresh, M. R. Manjunatha, Shridhar Narayanan, K.R. Prabhakar, Khisi Mdluli, Sreevalli Sharma, James D. Whiteaker, Scott Butler, Pravin S. Shirude, Radha Shandil, Vaishali Humnabadkar, Monalisa Chatterji, Abhishek Srivastava, Ramanatha Saralaya, Jitendar Reddy, Robert E. McLaughlin, Christopher B. Cooper, Vasan K. Sambandamurthy
Publikováno v:
Journal of medicinal chemistry. 57(13)
In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2'-epimerase (DprE1). Nevertheless,